血友病基因治疗概览:导航创新的问题与解答
本文综述血友病基因治疗进展,聚焦AAV载体疗法的临床试验证据与多学科管理需求,指出AAV基因治疗可实现持续因子表达并减少出血,但转氨酶升高常见,长期耐久性、免疫反应和标准化诊疗路径仍待解决。
要点
- AAV基因治疗在血友病A和B中实现持续因子表达,因子水平达正常或轻型血友病范围。
- 约20%至90%的患者输注后出现转氨酶升高,需免疫抑制管理和肝脏监测。
- 长期耐久性、免疫反应和标准化诊疗路径仍是待解决的问题。
核心结论
- 血友病基因治疗已从实验概念演变为临床现实,提供持续止血保护并减少治疗负担。
- 当前AAV基因疗法是变革性进展,但长期耐久性、免疫反应和标准化诊疗路径仍存挑战。
研究设计与样本
- 本篇为教育性综述,聚焦腺相关病毒(AAV)为基础的基因治疗方法、临床实施及多学科照护需求。
主要发现
- AAV基因治疗在临床试验中显示持续因子表达,患者因子水平达正常或轻型血友病范围,出血率显著降低。
- valoctocogene roxaparvovec(血友病A)和etranacogene dezaparvovec(血友病B)的近期III期试验显示因子表达持久长达5年,FIX-Padua变异体使疗效增强5至8倍。
- 约20%至90%的血友病患者输注后出现转氨酶升高,需要免疫抑制管理和肝脏监测。
关键数值与推荐
- AAV基因治疗通过潜在一次性干预针对根本遗传病因。
- valoctocogene roxaparvovec用于血友病A,etranacogene dezaparvovec用于血友病B,III期试验显示因子表达持久长达5年。
- FIX-Padua变异体使治疗疗效增强5至8倍。
- 约20%至90%的患者输注后出现转氨酶升高。
临床怎么用
- 基因治疗需要多学科照护,包括免疫抑制管理和肝脏监测。
- 未来发展方向包括替代载体、增强型因子变异体和基因编辑技术。
局限性
- 长期耐久性、免疫反应和标准化诊疗路径仍存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia is a rare inherited bleeding disorder affecting approximately 1.1 million individuals worldwide, characterized by deficiency in clotting factor (F)VIII (hemophilia A) or FIX (hemophilia B). Despite advances in prophylactic factor replacement therapy and nonfactor treatments, persons with hemophilia continue to experience breakthrough bleeding, joint deterioration, and treatment burden, highlighting the need for transformative therapeutic approaches. This educational review provides a comprehensive overview of gene therapy developments for hemophilia, focusing on adenoassociated virus (AAV)-based approaches, their clinical implementation, and multidisciplinary care requirements. Gene therapy represents a paradigm shift in hemophilia treatment by addressing the underlying genetic cause through a potentially 1-time intervention. AAV-based gene therapies have demonstrated sustained factor expression in clinical trials, with persons with hemophilia, achieving factor levels in the normal or mild hemophilia range and significant reductions in bleeding rates. Recent phase III trials of valoctocogene roxaparvovec (hemophilia A) and etranacogene dezaparvovec (hemophilia B) have shown durable factor expression for up to 5 years, with the FIX-Padua variant enhancing treatment efficacy 5- to 8-fold. However, approximately 20% to 90% of persons with hemophilia experience transaminase elevation postinfusion, requiring immunosuppressive management and hepatologic monitoring. Gene therapy for hemophilia has evolved from experimental concept to clinical reality, offering sustained hemostatic protection with reduced treatment burden. While challenges remain regarding long-term durability, immune responses, and standardized care pathways, current AAV-based therapies represent a transformative advance. Future developments including alternative vectors, enhanced factor variants, and gene editing technologies promise to further improve treatment outcomes and expand patient access.
引用
- Hoffmann P, Bitto N, La Mura V, et al. Overview of gene therapy for hemophilia: questions and answers to navigate the innovation. J Thromb Haemost. 2025. PMID: 41448545. doi:10.1016/j.jtha.2025.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。